bullish
Chugai Pharmaceutical (4519 JP): Export Drives Growth; New Products To Relieve Domestic Market Pain
215 Views29 Oct 2024 22:56
SUMMARY
- Chugai Pharmaceutical (4519 JP) reported 3Q24 revenue of ¥315.7B, up 22% YoY, beating estimates, majorly on the back of robust overseas sales, which grew 45% YoY to ¥150B.
- Hemlibra export and new launches such as Vabysmo, Phesgo, Polivy, and Alecensa are expected to drive growth in the medium to long term trajectory.
- Chugai made an upward revision of 2024 guidance due to strength in overseas market. 2024 revenue and core operating profit are now expected to increase 3% and 20%, YoY, respectively.
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Rising
Tina Banerjee
Global Healthcare Analyst
Price Chart(Sign Up to Access)
- Chugai Pharmaceutical (4519 JP): Ronapreve Killed Joy in 2023; New Products to Drive Growth Ahead08 Feb 2024
- Chugai Pharmaceutical (4519 JP): Hemlibra Is the Only Saviour; Competition Bites Mainstay Drugs22 Jan 2023
- Chugai Pharmaceutical (4519 JP) 1Q22: Sales Growth Outshined by Weaker Margin; Guidance Unchanged17 May 2022
x